Cases & Deals

BioMarin acquires LEAD Therapeutics

Clients BioMarin Pharmaceutical, Inc.

Jones Day advised BioMarin Pharmaceutical, Inc. in connection with the acquisition of LEAD Therapeutics, Inc., a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers. BioMarin will pay to the stockholders of LEAD $18 million upfront and will pay an additional $11 million upon acceptance of the investigational new drug filing (filing expected by the end of 2010), and up to $68 million for development and launch milestones for LT-673.